夏丽, 竟雪莹. 重组人尿激酶原治疗急性ST段抬高型心肌梗死的临床研究[J]. 蚌埠医科大学学报, 2023, 48(5): 601-605. DOI: 10.13898/j.cnki.issn.1000-2200.2023.05.011
    引用本文: 夏丽, 竟雪莹. 重组人尿激酶原治疗急性ST段抬高型心肌梗死的临床研究[J]. 蚌埠医科大学学报, 2023, 48(5): 601-605. DOI: 10.13898/j.cnki.issn.1000-2200.2023.05.011
    XIA Li, JING Xue-ying. Clinical study of recombinant human prourokinase in the treatment of acute ST-segment elevation myocardial infarction[J]. Journal of Bengbu Medical University, 2023, 48(5): 601-605. DOI: 10.13898/j.cnki.issn.1000-2200.2023.05.011
    Citation: XIA Li, JING Xue-ying. Clinical study of recombinant human prourokinase in the treatment of acute ST-segment elevation myocardial infarction[J]. Journal of Bengbu Medical University, 2023, 48(5): 601-605. DOI: 10.13898/j.cnki.issn.1000-2200.2023.05.011

    重组人尿激酶原治疗急性ST段抬高型心肌梗死的临床研究

    Clinical study of recombinant human prourokinase in the treatment of acute ST-segment elevation myocardial infarction

    • 摘要:
      目的评估急性ST段抬高型心肌梗死(STEMI)病人行急诊经皮冠状动脉介入治疗(PCI)术中给予冠状动脉内注射重组人尿激酶原溶栓的有效性和安全性。
      方法126例中观察组61例,冠状动脉造影发现罪犯血管后给予重组人尿激酶原20 mg,10 min后再次造影,观察冠状动脉血流,评估冠状动脉血管病变情况后选择合适的支架植入;对照组65例,冠状动脉造影发现罪犯血管后根据冠状动脉血管病变情况直接选择合适支架植入。比较2组病人术后ST段回落率、肌钙蛋白I峰值和肌酸激酶同工酶水平、心功能指标、住院期间出血事件和主要不良心血管事件(MACEs)及术后随访1、6个月MACEs发生情况。
      结果观察组血清肌酸激酶同工酶和肌钙蛋白I峰值水平均低于对照组(P < 0.05),ST段完全回落(≥70%)多于对照组(P < 0.05)。2组病人PCI术后1 d左心室射血分数(LVEF)和舒张末期内径(LVEDd)差异均无统计学意义(P>0.05),观察组N端脑钠肽前体水平低于对照组(P < 0.05);术后1个月,观察组LVEF和LVEDd均优于对照组(P < 0.05)。2组病人住院期间出血事件和MACEs差异均无统计学意义(P>0.05),随访1、6个月时MACEs发生率差异亦均无统计学意义(P>0.05)。
      结论PCI术中经球囊导管冠状动脉内应用尿激酶原可有效改善STEMI病人心肌灌注及近期心功能,且不增加出血风险。

       

      Abstract:
      ObjectiveTo evaluate the efficacy and safety of intracoronary thrombolysis with recombinant human prourokinase during emergency percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).
      MethodsA total of 126 patients, including 61 patients in the observation group.After the discovery of the criminal's blood vessels by coronary angiography, 20 mg of recombinant human prourokinase was administered in the coronary arteries, and an appropriate amount of contrast agent was injected again 10 minutes later to observe the coronary blood flow, and appropriate stent implantation was selected according to the pathological conditions of the coronary arteries.In the control group, 65 patients were directly selected for stent implantation according to the coronary artery lesions after coronary angiography was found.The recovery rate of ST-segment, the peak value of TnI and CK-MB, the cardiac function, bleeding events during hospitalization, major adverse cardiovascular events (MACEs) and MACEs at 1 month after operation were compared and observed between the two groups.
      ResultsThe peak levels of serum CK-MB and TnI in the observation group were significantly lower than those in the control group(P < 0.05).The falling rate of ST-segment in the observation group was significantly higher than that in the control group(P < 0.05).There was no significant difference in the levels of left ventricular ejection fractions (LVEF) and left ventricular end-diastolic dimension (LVEDd) between the two groups on the first day after PCI operation(P>0.05), and the NT-proBNP content in the observation group was lower than that in the control group (P < 0.05).One month after operation, the levels of LVEF and LVEDd in the observation group were significantly better than those in the control group(P < 0.05).There was no significant difference in the incidence of bleeding events and MACEs during hospitalization and the incidence of MACEs one month and six months after operation between the two groups.
      ConclusionsIntracoronary administration of prourokinase via balloon catheter during primary PCI can effectively improve myocardial perfusion and short-term cardiac function in patients with STEMI without increasing the risk of bleeding.

       

    /

    返回文章
    返回